Baricitinib set to join the Covid-19 therapeutic arsenal?

Rheumatology (Oxford). 2021 Apr 6;60(4):1585-1587. doi: 10.1093/rheumatology/keab061.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / immunology
  • Antiviral Agents / pharmacology
  • Azetidines* / immunology
  • Azetidines* / pharmacology
  • COVID-19 Drug Treatment*
  • COVID-19* / immunology
  • Clinical Trials as Topic
  • Humans
  • Immunologic Factors / pharmacology
  • Intracellular Signaling Peptides and Proteins / antagonists & inhibitors
  • Janus Kinase Inhibitors / pharmacology
  • Protein Serine-Threonine Kinases / antagonists & inhibitors
  • Purines* / immunology
  • Purines* / pharmacology
  • Pyrazoles* / immunology
  • Pyrazoles* / pharmacology
  • SARS-CoV-2 / drug effects*
  • Sulfonamides* / immunology
  • Sulfonamides* / pharmacology
  • Treatment Outcome

Substances

  • Antiviral Agents
  • Azetidines
  • Immunologic Factors
  • Intracellular Signaling Peptides and Proteins
  • Janus Kinase Inhibitors
  • Purines
  • Pyrazoles
  • Sulfonamides
  • AAK1 protein, human
  • GAK protein, human
  • Protein Serine-Threonine Kinases
  • baricitinib